Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Recent studies have demonstrated that allogeneic hematopoietic stem cell transplantation
(allo-HSCT) could be a valuable treatment choice for myeloid tumors, such as acute myeloid
leukemia and myelodysplastic syndrome. Unfortunately, some patients relapsed after allo-HSCT.
In this prospective randomized controlled study, the safety and efficacy of Decitabine + BUCY
and BUCY myeloablative conditioning regimens in myeloid tumors undergoing allo-HSCT are
evaluated.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
Peking University People's Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Third Affiliated Hospital, Sun Yat-Sen University Zhujiang Hospital